Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

Kristin Jensen / healthcaredive - A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

AI Summary: Moderna has initiated a clinical trial of an mRNA vaccine targeting a potentially pandemic bird‑flu strain, joining global efforts to have a rapid‑response countermeasure ready. Regulators and public‑health experts hail the move as sensible pre‑emptive science—because nothing says “we planned for this” like testing the vaccine before the outbreak arrives.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Pfizer's Lyme vaccine heads to FDA after mixed trial results / 2 months

Favipiravir shows promise in Lassa fever Phase 2 trial / 15 days

One hepatitis B drug shows early functional cures in trial / 2 days

Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 15 days

Vanderbilt’s experimental C. diff vaccine shows promising protection / 3 months

Nasal-spray ‘universal’ vaccine protects mice from many respiratory threats / 3 months

FDA approves Merck’s once‑daily two‑drug HIV pill, shaking up market / 5 wks